We report the use of bevacizumab (Avastin) as an additional strategy in angle closure glaucoma based on the case of 47 years old male qualified to cataract removal as anti-glaucoma procedure, in whom we observed iris and lens neovascularization. As a first step we administered 1.25 mg of bevacizumab into the anterior chamber. Iris as well as lens neovasularization completely disappeared after 4...

Neovascularization of the iris was induced in cats by removing the vitreous and lens and creating a rhegmatogenous retinal detachment. The presence of new blood vessels on the anterior surface of the iris was verified from the second month onward by slit lamp examination, as well as by light microscopy six to twelve months after the operation. Control eyes undergoing vitrectomy and lensectomy, ...

A patient is reported in whom the clinical observation of extension of the corneal endothelium and Descemet's membrane in association with rubeosis iridis was confirmed by histopathological examination. In a study of eyes which had been removed and demonstrated rubeosis iridis and secondary glaucoma in 16 additional eyes revealed extension of the corneal endothelium and Descemet's membrane on t...

PURPOSE To characterize the onset and type of neovascular events in eyes with central retinal vein occlusion (CRVO) undergoing serial anti-VEGF therapy. METHODS Consecutive eyes undergoing serial intravitreal bevacizumab or ranibizumab injections for treatment of CME secondary to CRVO were identified. Pertinent data was retrospectively collected and included type and onset of the neovascular ...

The permeability of the ocular blood vessels to sodium fluorescein (NaFl) was evaluated in neonatal and adult cats by fluorescence microscopy. The iris, ciliary body, and choroidal vessels were markedly permeable, whereas the mature and immature retinal vessels were impermeable. Since there is no apparent barrier to NaFl at the level of the iris vessels, the role of those vessels in aqueous for...

BACKGROUND AND OBJECTIVE To determine the efficacy of off-label intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal vascular diseases. PATIENTS AND METHODS Retrospective, non-comparative, open-label, interventional, consecutive case series of all patients younger than 18 years treated with off-label IVB at a single center from January 1, 2005, to January 1, 200...

PURPOSE To prospectively evaluate the effect of 1.25 mg and 2.5 mg intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma (NVG), with primary outcome measures being the regression of neovascularization of iris (NVI) and reduction of intraocular pressure (IOP). METHODS Consecutive patients with neovascular glaucoma from December 2006 to March 2007 were randomi...

We report three cases of neovascular glaucoma secondary to central retinal artery occlusion (CRAO) which were effectively managed with intravitreal bevacizumab (IVB) followed by panretinal photocoagulation (PRP). Neovascular glaucoma without peripheral anterior synechiae developed between one and five weeks following CRAO onset. All patients received 0.75 mg (0.03 ml) IVB. In all patients, comp...

Introduction: Chorioretinal coloboma (CRC) results from abnormal closure of the embryonic fissure. Choroidal neovascularization (CNV) is a rare complication that associated with choroid. VEGF an important factor in development CNV.
 Case Report: A 52-year-old woman gradual blurred vision left eye since 4 months ago. Right was already she child uncorrected visual acuity (UCVA) 0.5/60. Her r...